Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
clinical trials
ipo
life sciences
national blog main
sanofi
4
×
boston top stories
cancer drugs
national top stories
san francisco blog main
san francisco top stories
deals
fda
investing
new york blog main
new york top stories
revolution medicines
san francisco
takeda pharmaceutical
the column group
third rock ventures
venture capital
warp drive bio
abbvie
agios pharmaceuticals
akouos
allergan
alnylam pharmaceuticals
amag pharmaceuticals
amgen
amunix
anirvan ghosh
astrazeneca
biogen
bluerock therapeutics
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
What
ipo
4
×
medicines
cancer
proteins
research
revolution
acquisitions
announced
bio
cancer’s
ceo
collabs
company’s
course
covid
daniel
deal
despite
development
discover
disease
drug
experimental
family
frontiers
gilead
gilead’s
growing
handiwork
hardest
help
helped
hit
hottest
hunters
internal
introduce
known
landscape
maps
Language
unset
Current search:
sanofi
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline